Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Authors
Keywords
PI3K/Akt/mTOR signaling, Human cancer, Hyperactivation, Targeted therapy, Inhibitors, Combination therapy, Biomarker
Journal
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-06-25
DOI
10.1016/j.semcancer.2021.06.019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical evaluation and Phase 1b study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor
- (2021) David S. Hong et al. CLINICAL CANCER RESEARCH
- Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
- (2021) Yu-xiang Wang et al. Cell Death & Disease
- Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
- (2021) Jian Wang et al. Oncogenesis
- The Roles of Post-Translational Modifications on mTOR Signaling
- (2021) Shasha Yin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
- (2021) Neel D. Trivedi et al. Cancer Medicine
- SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
- (2021) Xi Zhang et al. ACTA PHARMACOLOGICA SINICA
- Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients
- (2020) Wang Jiangyi et al. Aging-US
- A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration resistant prostate cancer.
- (2020) M.P. Kolinsky et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
- (2020) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PIK3CA gene aberrancy and role in targeted therapy of solid malignancies
- (2020) Owen Willis et al. CANCER GENE THERAPY
- First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma
- (2020) Patrick Y. Wen et al. CLINICAL CANCER RESEARCH
- Wnt/beta-catenin and PI3K/Akt/mtor Signaling Pathways in Glioblastoma: Two main targets for drug design: A Review
- (2020) Seyed Hossein Shahcheraghi et al. CURRENT PHARMACEUTICAL DESIGN
- Isoform-Selective PI3K Inhibitors for Various Diseases
- (2020) Rammohan R. Yadav Bheemanaboina CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
- (2020) Binquan Wu et al. Expert Opinion on Drug Delivery
- Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
- (2020) F. Coussy et al. Journal of Hematology & Oncology
- Targeting AKT/PKB to improve treatment outcomes for solid tumors
- (2020) M. Iida et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control
- (2020) Wenjian Gan et al. NATURE CELL BIOLOGY
- mTOR at the nexus of nutrition, growth, ageing and disease
- (2020) Grace Y. Liu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
- (2020) Fan Li et al. ONCOGENE
- Copanlisib: Novel PI3K Inhibitor for Treatment of Lymphoma.
- (2020) Anshul Kumar et al. Anti-Cancer Agents in Medicinal Chemistry
- A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
- (2020) Eleftherios Kostaras et al. BRITISH JOURNAL OF CANCER
- A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
- (2020) Mojun Zhu et al. INVESTIGATIONAL NEW DRUGS
- Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
- (2020) Nicci Owusu-Brackett et al. Oncotarget
- Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4
- (2020) Li-Hua Sun et al. Scientific Reports
- Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer
- (2020) Jun Chang et al. Cancer Management and Research
- First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
- (2020) Robert McLeod et al. CLINICAL CANCER RESEARCH
- Copanlisib in the treatment of non-Hodgkin lymphoma
- (2020) Mayur Narkhede et al. Future Oncology
- Nanotechnology-Based Targeting of mTOR Signaling in Cancer
- (2020) Mee-Sup Yoon International Journal of Nanomedicine
- Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
- (2020) Kai Chen et al. LIFE SCIENCES
- STAT3‐mediated MLST8 gene expression regulates cap‐dependent translation in cancer cells
- (2020) Hyunji Lee et al. Molecular Oncology
- Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells
- (2020) Mohamed E. Abdallah et al. MOLECULES
- cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy
- (2020) Wenwen Li et al. Science Translational Medicine
- AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway
- (2020) Lun Gao et al. Frontiers in Pharmacology
- Experimental Approaches in Delineating mTOR Signaling
- (2020) Jiayi Qian et al. Genes
- Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
- (2020) Douglas K. Marks et al. Frontiers in Oncology
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
- (2020) Hye Ryun Kim et al. BRITISH JOURNAL OF CANCER
- Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
- (2020) Susana Ros et al. CANCER CELL
- Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance
- (2020) Tzu-Ting Huang et al. CANCER RESEARCH
- mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
- (2020) Niklas Gremke et al. Nature Communications
- Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
- (2020) Monique Bernard et al. Cancers
- Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
- (2020) Ying Chen et al. Frontiers in Cell and Developmental Biology
- PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
- (2020) Sadegh Fattahi et al. LIFE SCIENCES
- Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4 /6 Inhibitor Therapy
- (2020) Madeline M. Cook et al. ONCOLOGIST
- Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
- (2020) Yumi Fujimoto et al. Scientific Reports
- Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
- (2020) Shu Wang et al. Biomed Research International
- SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia
- (2020) Lei Fan et al. NEOPLASIA
- Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
- (2020) S. Dent et al. ANNALS OF ONCOLOGY
- Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
- (2019) Takuro Yamamoto et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer
- (2019) Angela Esposito et al. JAMA Oncology
- Identification of recurrent fusion genes across multiple cancer types
- (2019) Yan-Ping Yu et al. Scientific Reports
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- Patient-driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-driven Cancer
- (2019) Emily K Slotkin et al. Cancer Discovery
- Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
- (2019) Carolina Caro-Vegas et al. mBio
- Mechanisms of PTEN loss in cancer: It’s all about diversity
- (2019) Virginia Álvarez-Garcia et al. SEMINARS IN CANCER BIOLOGY
- PTEN arginine methylation by PRMT6 suppresses PI3K–AKT signaling and modulates pre-mRNA splicing
- (2019) Jiawen Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Control of mTOR signaling by ubiquitin
- (2019) Yao Jiang et al. ONCOGENE
- Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer
- (2019) Xiaobing Shen et al. Future Oncology
- Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN–AKT axis
- (2019) Jossimar Coronel-Hernández et al. Cancer Cell International
- Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy
- (2019) Yeying Liu et al. Cancer Cell International
- PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells
- (2019) Felicitas Bossler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
- (2019) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- Paired Genomic Analysis of Squamous Cell Carcinoma Transformed From EGFR-mutated Lung Adenocarcinoma
- (2019) Sehhoon Park et al. LUNG CANCER
- PI3K isoforms in cell signalling and vesicle trafficking
- (2019) Benoit Bilanges et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
- (2019) Yi-Hui Wu et al. Cell Death & Disease
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II
- (2019) Shanshan Zhao et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features
- (2019) Qingqing Ding et al. HUMAN PATHOLOGY
- Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
- (2019) Corey J. Langer et al. Journal of Thoracic Oncology
- Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging
- (2019) Yiming Li et al. NEURORADIOLOGY
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- (2019) Hang Zhao et al. OncoTargets and Therapy
- MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
- (2019) Yao Jiang et al. Nature Communications
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
- (2019) Richard D. Baird et al. CLINICAL CANCER RESEARCH
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors
- (2019) Xueqiong Zhang et al. JOURNAL OF CONTROLLED RELEASE
- A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1
- (2019) Xin Xia et al. Molecular Cancer
- A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
- (2019) Edward Wolin et al. PLoS One
- mTOR: Role in cancer, metastasis and drug resistance
- (2019) Avaniyapuram Kannan Murugan SEMINARS IN CANCER BIOLOGY
- Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
- (2019) M Brandão et al. ANNALS OF ONCOLOGY
- Distinct functions of AKT isoforms in breast cancer: a comprehensive review
- (2019) Nico Hinz et al. Cell Communication and Signaling
- Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency
- (2019) Chien-Ju Chen et al. NATURE MEDICINE
- Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- (2019) Neil Vasan et al. SCIENCE
- Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation
- (2019) Joséphine Briand et al. Clinical Epigenetics
- FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland
- (2019) Yasuhiro Isono et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
- (2019) Andrea P. Myers et al. INTERNATIONAL JOURNAL OF CANCER
- Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Steven T. Bird et al. JAMA Oncology
- Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer
- (2018) Troels Dreier Christensen et al. ACTA ONCOLOGICA
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia
- (2018) Bahareh Toosi et al. BIOMEDICINE & PHARMACOTHERAPY
- MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer
- (2018) Manxin Xie et al. BIOMEDICINE & PHARMACOTHERAPY
- Overexpression of long non-coding RNA H19 promotes invasion and autophagy via the PI3K/AKT/mTOR pathways in trophoblast cells
- (2018) Jin Xu et al. BIOMEDICINE & PHARMACOTHERAPY
- An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation
- (2018) Jeffrey J. Heard et al. BMC CANCER
- Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
- (2018) Karineh Petrossian et al. BREAST CANCER RESEARCH AND TREATMENT
- Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
- (2018) Xue-ling Liu et al. CANCER LETTERS
- Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
- (2018) Hideki Makinoshima et al. CANCER RESEARCH
- Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
- (2018) Maura N. Dickler et al. CLINICAL CANCER RESEARCH
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
- (2018) Chuanyao Cheng et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
- (2018) Songlin Liu et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Matrine reversed multidrug resistance of breast cancer MCF-7/ADR cells through PI3K/AKT signaling pathway
- (2018) Bing-Gang Zhou et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry
- (2018) Md. Mamunur Rashid et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
- (2018) Jianbiao Zhou et al. Journal of Hematology & Oncology
- Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex
- (2018) Shan Gao et al. MEDICINE
- The mTOR–S6K pathway links growth signalling to DNA damage response by targeting RNF168
- (2018) Xiaoduo Xie et al. NATURE CELL BIOLOGY
- The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- (2018) Yu-Ru Lee et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- OUP accepted manuscript
- (2018) NUCLEIC ACIDS RESEARCH
- Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
- (2018) Timothy McKinnon et al. ONCOGENE
- MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN
- (2018) Julia Ramírez-Moya et al. ONCOGENE
- Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway
- (2018) Ramón García-Escudero et al. ORAL ONCOLOGY
- RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer
- (2018) Said El Shamieh et al. PHARMACOGENOMICS
- Interest of next-generation sequencing in BCG-treated high-risk bladder cancer
- (2018) C. Jungels et al. PROGRES EN UROLOGIE
- The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth
- (2018) Jianjun Zhang et al. Science Signaling
- PDK1: At the crossroad of cancer signaling pathways
- (2018) Paolo Armando Gagliardi et al. SEMINARS IN CANCER BIOLOGY
- Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
- (2018) Dongshao Chen et al. Cell Death & Disease
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
- (2018) Li Chen et al. Nature Communications
- Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
- (2018) Arnon P. Kater et al. Blood Cancer Journal
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
- (2018) Ning Wu et al. Journal of Cancer
- The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth
- (2018) Jianjun Zhang et al. Science Signaling
- Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
- (2018) Xiaoxiao Wang et al. NEOPLASIA
- PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue
- (2018) Tomoya Yokota et al. BMC CANCER
- Regulation of PTEN expression by noncoding RNAs
- (2018) Wang Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
- (2018) Claudia Brandt et al. NEUROPHARMACOLOGY
- HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
- (2018) Shixiu Sun et al. Cell Death & Disease
- IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
- (2018) Jonatan Zorea et al. Cell Death & Disease
- MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN
- (2018) Hui Lin et al. Scientific Reports
- Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency
- (2018) Anida Hasanovic et al. Cells
- Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
- (2018) Silvia L. Locatelli et al. CLINICAL CANCER RESEARCH
- Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
- (2018) Sarah P Blagden et al. CLINICAL CANCER RESEARCH
- Long noncoding RNA OIP5‐AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR‐340‐5p
- (2018) Lei Song et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly
- (2018) Lara Rodriguez-Laguna et al. JOURNAL OF EXPERIMENTAL MEDICINE
- mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
- (2018) Stacia L. Koppenhafer et al. MOLECULAR CANCER THERAPEUTICS
- MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers
- (2018) Stephanie L. Fricke et al. MOLECULAR CANCER THERAPEUTICS
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer
- (2018) Sheng Chen et al. Cell Death & Disease
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
- (2017) Paula Fontes Asprino et al. ENDOCRINE-RELATED CANCER
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- miR-103 Promotes Proliferation and Metastasis by Targeting KLF4 in Gastric Cancer
- (2017) Jie Zheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Analysis of TSC1 mutation spectrum in mucosal melanoma
- (2017) Meng Ma et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- (2017) Shanshan Zhang et al. JOURNAL OF HEPATOLOGY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
- (2017) Paul A. VanderLaan et al. LUNG CANCER
- Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
- (2017) Ümmügülsüm Yesilöz et al. NEURO-ONCOLOGY
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- (2017) T Fujishita et al. ONCOGENE
- Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway
- (2017) Jiumao Lin et al. ONCOLOGY REPORTS
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
- (2017) Elisa Oricchio et al. Science Translational Medicine
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
- (2017) Trisha M. Wise-Draper et al. Targeted Oncology
- Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
- (2017) Winn Aung et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- The genomic landscape of tuberous sclerosis complex
- (2017) Katie R. Martin et al. Nature Communications
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer
- (2017) Karina J. Matissek et al. Cancer Discovery
- Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
- (2017) King Xin Koh et al. Oncotarget
- PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
- (2017) Liyan Chen et al. Oncotarget
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
- (2017) Masayuki Yamaji et al. Cancer Medicine
- MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway
- (2017) Yuan Miao et al. Scientific Reports
- Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
- (2016) Ashish Kulkarni et al. ACS Nano
- Rapamycin-insensitive companion of mTOR ( RICTOR ) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition
- (2016) S. T. Kim et al. ANNALS OF ONCOLOGY
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2016) Sarah K. Tasian et al. BLOOD
- Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
- (2016) R. Thijssen et al. BLOOD
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
- (2016) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
- (2016) D. J. Kwiatkowski et al. CLINICAL CANCER RESEARCH
- TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication
- (2016) Daniel W H Ho et al. GUT
- The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells
- (2016) Haiying Wang et al. Hematology
- The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
- (2016) Timothy P. Heffron et al. JOURNAL OF MEDICINAL CHEMISTRY
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer
- (2016) Fernanda Musa et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
- (2016) M. C. Smith et al. MOLECULAR CANCER THERAPEUTICS
- Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling
- (2016) L Du et al. ONCOGENE
- Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth
- (2016) Y Wang et al. ONCOGENE
- The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
- (2016) Ismael Riquelme et al. PATHOLOGY & ONCOLOGY RESEARCH
- AKT1E17K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
- (2016) Donatella Malanga et al. PLoS One
- Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers
- (2016) Babak Alaei-Mahabadi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2
- (2016) Yong-Bin Zheng et al. Oncology Letters
- A genetic basis for the variation in the vulnerability of cancer to DNA damage
- (2016) Brian D. Yard et al. Nature Communications
- Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
- (2016) Maria L. Mancini et al. Oncotarget
- Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer
- (2016) Romana Moench et al. Oncotarget
- Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
- (2016) Sun Min Lim et al. Oncotarget
- Association ofMTORMutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
- (2016) Ghayda M. Mirzaa et al. JAMA Neurology
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer
- (2016) Si-Hyong Jang et al. Journal of Gastric Cancer
- Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers
- (2015) Bernard Barlaam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescencein situhybridization impact on prognosis in breast cancer
- (2015) Jiao Li et al. CANCER SCIENCE
- Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
- (2015) Z. S. Zumsteg et al. CLINICAL CANCER RESEARCH
- Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
- (2015) C. P. Hall et al. CLINICAL CANCER RESEARCH
- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
- (2015) Ursula Matulonis et al. GYNECOLOGIC ONCOLOGY
- Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines
- (2015) Laura Lattanzio et al. INVESTIGATIONAL NEW DRUGS
- The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
- (2015) Zhi Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease
- (2015) Kenneth Down et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers
- (2015) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy
- (2015) Maddalena Mognato et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
- (2015) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair
- (2015) Pengda Liu et al. MOLECULAR CELL
- MAGI3–AKT3 fusion in breast cancer amended
- (2015) Juan-Miguel Mosquera et al. NATURE
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- RecurrentBCAM-AKT2fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma
- (2015) Kalpana Kannan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The butterfly effect in cancer: A single base mutation can remodel the cell
- (2015) Jonathan R. Hart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
- (2015) Haluk Yuzugullu et al. Nature Communications
- RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
- (2015) H. Cheng et al. Cancer Discovery
- Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
- (2015) Xiao-jun Qian et al. Oncotarget
- Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
- (2015) Arindam P. Ghosh et al. Oncotarget
- Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis
- (2015) Elizabeth L. Yanik et al. Cancer Medicine
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
- (2014) Claudia Fumarola et al. BIOCHEMICAL PHARMACOLOGY
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis
- (2014) Wenjia Wang et al. BMC CANCER
- Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway
- (2014) Hua Sui et al. BMC Complementary and Alternative Medicine
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
- (2014) Sara Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
- (2014) V D'Amato et al. BRITISH JOURNAL OF CANCER
- Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
- (2014) Eva Maria Ciruelos Gil CANCER TREATMENT REVIEWS
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
- (2014) A. D. Bucheit et al. CLINICAL CANCER RESEARCH
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
- (2014) T. A. Yap et al. CLINICAL CANCER RESEARCH
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex
- (2014) Heung-Mo Yang et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
- (2014) Alexandre A. B. A. da Costa et al. International Journal of Clinical Oncology
- PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
- (2014) Prabhakar Mithal et al. INTERNATIONAL JOURNAL OF UROLOGY
- Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer
- (2014) Jun Qin et al. JOURNAL OF CLINICAL INVESTIGATION
- Milestones in the Use of Combined-Modality Radiation Therapy and Chemotherapy
- (2014) Theodore S. Lawrence et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
- (2014) Timothy D. Cushing et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2014) Pasi A. Jänne et al. Journal of Thoracic Oncology
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer
- (2014) Benjamin Levy et al. Journal of Thoracic Oncology
- Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
- (2014) Kyriakos P. Papadopoulos et al. LEUKEMIA & LYMPHOMA
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer
- (2014) Qing-Ying Zhang et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
- (2014) Pengda Liu et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma
- (2014) Qiang Xie et al. NEUROPATHOLOGY
- AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake
- (2014) Ramachandran Rashmi et al. PLoS One
- The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
- (2014) Khalil A. Choucair et al. Translational Oncology
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
- (2014) Paraskevi Gkeka et al. PLoS Computational Biology
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients
- (2013) Wei-feng Wang et al. ACTA PHARMACOLOGICA SINICA
- Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers
- (2013) Ju-yeon Jeong et al. APOPTOSIS
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- Where Birt–Hogg–Dubé meets Cowden Syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours
- (2013) Laura Maria Pradella et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Birt–Hogg–Dubé syndrome is a novel ciliopathy
- (2013) Monique N.H. Luijten et al. HUMAN MOLECULAR GENETICS
- Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
- (2013) Ryan P. P. Shugg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ActivatingAKT2Mutation: Hypoinsulinemic Hypoketotic Hypoglycemia
- (2013) Ved Bhushan Arya et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
- (2013) Jing Li et al. Journal of Translational Medicine
- Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential
- (2013) L M Neri et al. LEUKEMIA
- A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells
- (2013) Per Johnsson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies
- (2013) R Vander Broek et al. ORAL DISEASES
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- MiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression
- (2013) Chitose Oneyama et al. PLoS One
- A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
- (2013) B. D. Hopkins et al. SCIENCE
- AKT Facilitates EGFR Trafficking and Degradation by Phosphorylating and Activating PIKfyve
- (2013) E. E. Er et al. Science Signaling
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
- (2013) Mi Kwon Son et al. Scientific Reports
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer
- (2012) Jing Shi et al. BMC CANCER
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
- (2012) Mary Maluccio et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis
- (2012) Hyunseung Lee et al. CANCER LETTERS
- High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation
- (2012) Niki Tzenaki et al. FASEB JOURNAL
- Genetic disruption of the PI3K regulatory subunits, p85 , p55 , and p50 , normalizes mutant PTPN11-induced hypersensitivity to GM-CSF
- (2012) C. B. Goodwin et al. HAEMATOLOGICA
- PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma
- (2012) Azusa Abe et al. HUMAN PATHOLOGY
- PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics
- (2012) Kiran Mahajan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
- (2012) Justin Cidado et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
- (2012) Vassiliki Papadimitrakopoulou Journal of Thoracic Oncology
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
- (2012) Jing Ni et al. Cancer Discovery
- Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors
- (2011) Deborah S. Mortensen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
- (2011) Didier Roulin et al. Molecular Cancer
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome
- (2011) Marjorie J. Lindhurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion
- (2011) Y Gu et al. ONCOGENE
- Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling
- (2011) C Garofalo et al. ONCOGENE
- Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination
- (2011) H. Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells
- (2010) Fengxue Zhang et al. CANCER BIOLOGY & THERAPY
- B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer
- (2010) Jing Tan et al. CANCER CELL
- Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway
- (2010) Lijun He et al. CANCER SCIENCE
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions
- (2010) John M.S. Bartlett Clinical Breast Cancer
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
- (2010) P. Wu et al. CURRENT MEDICINAL CHEMISTRY
- Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
- (2010) Sauveur-Michel Maira et al. Future Medicinal Chemistry
- ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
- (2010) Audrey Carriere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PTEN mutation spectrum in breast cancers and breast hyperplasia
- (2010) JuLun Yang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
- (2010) Sara M. Johnson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
- (2010) Benjamin Solomon et al. Journal of Thoracic Oncology
- MEK1 and AKT2 Mutations in Japanese Lung Cancer
- (2010) Hidefumi Sasaki et al. Journal of Thoracic Oncology
- Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
- (2010) Christina Barbara Ching et al. LABORATORY INVESTIGATION
- Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction
- (2010) Daming Gao et al. MOLECULAR CELL
- A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
- (2010) Laura Poliseno et al. NATURE
- Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
- (2010) J Lauring et al. ONCOGENE
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Up-regulation of PIK3CA promotes metastasis in gastric carcinoma
- (2010) Ji-Fang Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- The Methylation of the TSC2 Promoter Underlies the Abnormal Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells
- (2009) Elena Lesma et al. AMERICAN JOURNAL OF PATHOLOGY
- Evidence-Based Surgical Care and the Evolution of Fast-Track Surgery
- (2009) Henrik Kehlet et al. ANNALS OF SURGERY
- Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma
- (2009) R. Hino et al. CANCER RESEARCH
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Oncogenic Ras, but not V600EB-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells
- (2009) L. Calleros et al. CARCINOGENESIS
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- Emerging common themes in regulation of PIKKs and PI3Ks
- (2009) Harri Lempiäinen et al. EMBO JOURNAL
- The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
- (2009) J. T. Huse et al. GENES & DEVELOPMENT
- Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma
- (2009) Akagi INTERNATIONAL JOURNAL OF ONCOLOGY
- The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells
- (2009) Li-Bing Song et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma
- (2008) Sanjukta Chakraborty et al. BMC CANCER
- Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival
- (2008) Hirozumi Sawai et al. BMC GASTROENTEROLOGY
- A novel AKT3 mutation in melanoma tumours and cell lines
- (2008) M A Davies et al. BRITISH JOURNAL OF CANCER
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling
- (2008) M. P. DeYoung et al. GENES & DEVELOPMENT
- Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells
- (2008) Masao Fujiwara et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers
- (2008) Q Zhu et al. ONCOGENE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex
- (2008) T. K. Neklesa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started